Phomaderide, a unique (6/5/4/5/6) spiro-cyclic dimer from the desert plant endophytic fungus Phoma betae A. B. Frank (Didymellaceae)

TL;DR

A desert plant fungus produces a unique spiro-cyclic compound with potential anticancer properties.

Contribution

Discovery of Phomaderide, a novel spiro-cyclic dimer with a unique (6/5/4/5/6) structure from Phoma betae.

Findings

Phomaderide is a unique spiro-cyclic dimer formed via [2+2] photocycloaddition of phaeosphaeride A.

Phomaderide and its analogs showed moderate cytotoxicity against HeLa and A549 cancer cells.

The BBMN strategy effectively isolated structurally related analogs from complex fungal extracts.

Abstract

Endophytic fungi from desert plants are prolific producers of structurally unique stress-responsive metabolites. This study investigates the secondary metabolites of Phoma betae A. B. Frank (Didymellaceae), a desert plant endophytic fungus, aiming to discover novel bioactive compounds through advanced molecular networking strategies.

A building blocks-based molecular network (BBMN) strategy was employed to screen the fungal extract. Target compounds were isolated using silica gel and ODS column chromatography, followed by semi-preparative HPLC purification. Structural elucidation was achieved through comprehensive NMR spectroscopy, mass fragmentation pathway analysis, and electronic circular dichroism (ECD) calculations. Cytotoxicity was evaluated against HeLa and A549 cancer cell lines using CCK-8 assays.

Three compounds were characterized:Phomaderide (3), a unique (6/5/4/5/6) spiro-cyclic dimer formed via stereoselective [2+2] photocycloaddition of two phaeosphaeride A (1) monomers. Its biosynthetic precursor phaeosphaeride A (1). A new hydroxylated analog, phaeosphaeride C (2). Compounds 2 and 3 exhibited moderate cytotoxicity against HeLa (IC50 29.97–39.15 μM) and A549 cells (IC50 30.47–58.33 μM).

This work highlights the metabolic versatility of extremophilic fungi, demonstrating Phoma betae's capacity to generate architecturally complex molecules. Phomaderide's unprecedented spiro-cyclic dimer scaffold positions it as a promising lead for anticancer drug discovery, with structural modifications (hydroxylation and dimerization) significantly influencing bioactivity. The BBMN strategy proved effective for targeted isolation of structurally related analogs from complex extracts.

Figures